Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 193

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 193
---
 or Pegasus, a company owned by certain of our founders, who are also shareholders,
including Eric Konofal, Eric-Jean Desbois, Bruno Figadere and our Chief Executive Officer, Alexander Zwyer, or the Pegasus Founders, entered
into a license agreement with AP-HP, or the AP-HP License Agreement, to obtain a worldwide, sub-licensable license, covering four different
compounds, which included the use of mazindol for the treatment of ADHD, or the Licensed Compounds. As part of the AP-HP License Agreement,
Pegasus was given an option to purchase the Licensed Compounds. In February 2016, after the AP-HP License Agreement was assigned and transferred
to NLS-1, pursuant to an Assignment and Transfer Agreement, or the ATA, NLS-1 purchased the Licensed Compounds from AP-HP for an aggregate
consideration of approximately 2.65 million euros, including reimbursement of certain expenses. On April 1, 2017 and September 20, 2019,
the parties entered into subsequent amendments of the ATA, or the First Amendment to the ATA and the Second Amendment to the ATA, respectively.
Under the Second Amendment to the ATA, NLS agreed to pay Pegasus a royalty of 1.8% of annual net sales (including sublicensee sales) realized
upon the commercialization of products developed on the basis of the Licensed Compounds during the terms of their respective patents;
provided, however, that under certain circumstances, the rate of the royalty payment will decrease. For instance, if a competing generic
product using mazindol for the treatment of ADHD were to become available during the term of the patents covering the Licensed Compounds,
there would be no royalties paid to Pegasus.

Exclusive License Agreement with Eurofarma

In February 2019, we
entered into a License Agreement with Eurofarma Laboratorios S. A., or Eurofarma and the EF License Agreement, which provided
Eurofarma with an exclusive, fee-bearing, non-transferrable (i) distribution right to distribute Nolazol in Latin America and an
(ii) exclusive, fee-bearing, non-transferrable license to our patents and trademarks in connection with the commercialization, if
any, of Nolazol in Latin America. The EF License Agreement is in effect until the later of either (i) ten years from the date of its
execution, or until